<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Syngene International Ltd. — News on 6ix</title>
<link>https://6ix.com/company/syngene-international-limited</link>
<description>Latest news and press releases for Syngene International Ltd. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 19 Feb 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/syngene-international-limited" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836501278dffbe2df15529a.webp</url>
<title>Syngene International Ltd.</title>
<link>https://6ix.com/company/syngene-international-limited</link>
</image>
<item>
<title>VivaMed BioPharma Partners With Syngene International to Advance AI-Derived Repurposed Therapeutic Programs Through Global Validation Infrastructure</title>
<link>https://6ix.com/company/syngene-international-limited/news/vivamed-biopharma-partners-with-syngene-international-to-advance-ai-derived-repurposed-therapeutic-programs-through-global-validation-infrastructure</link>
<guid isPermaLink="true">https://6ix.com/company/syngene-international-limited/news/vivamed-biopharma-partners-with-syngene-international-to-advance-ai-derived-repurposed-therapeutic-programs-through-global-validation-infrastructure</guid>
<pubDate>Thu, 19 Feb 2026 11:00:00 GMT</pubDate>
<description>SCOTTSDALE, Ariz., February 19, 2026--VivaMed BioPharma (VivaMed), a clinical-stage pharmaceutical company leveraging Artificial Intelligence (AI) to discover and advance repurposed and improved therapeutic assets, today announced a strategic partnership with Syngene International, a leading global contract research, development and manufacturing organization. The collaboration expands VivaMed’s validation infrastructure and reinforces its mission to deliver scientifically validated, partner-rea</description>
</item>
<item>
<title>Press Release Jan 22 2026</title>
<link>https://6ix.com/company/syngene-international-limited/news/press-release-jan-22-2026-6</link>
<guid isPermaLink="true">https://6ix.com/company/syngene-international-limited/news/press-release-jan-22-2026-6</guid>
<pubDate>Thu, 22 Jan 2026 23:36:48 GMT</pubDate>
<description>Syngene International Limited has informed the Exchange regarding a press release dated January 22, 2026, titled "Nine months revenue from operations up 3% year-on-year to Rs. 2,702 Cr - Third quarter revenue from operations down 3% year-on-year to Rs. 917 Cr".</description>
</item>
<item>
<title>Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035</title>
<link>https://6ix.com/company/syngene-international-limited/news/syngene-international-extends-long-term-174100746</link>
<guid isPermaLink="true">https://6ix.com/company/syngene-international-limited/news/syngene-international-extends-long-term-174100746</guid>
<pubDate>Tue, 20 Jan 2026 17:41:00 GMT</pubDate>
<description>Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery (chemistry, biology, drug metabolism and pharmacokinetics), translational sciences, pharmaceutical development and manufacturing, clinical trials, data and inf</description>
</item>
<item>
<title>Press Release Jan 19 2026</title>
<link>https://6ix.com/company/syngene-international-limited/news/press-release-jan-19-2026-6</link>
<guid isPermaLink="true">https://6ix.com/company/syngene-international-limited/news/press-release-jan-19-2026-6</guid>
<pubDate>Mon, 19 Jan 2026 14:30:42 GMT</pubDate>
<description>Syngene International Limited has informed the Exchange regarding a press release dated January 19, 2026, titled "Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035".</description>
</item>
<item>
<title>Press Release Nov 05 2025</title>
<link>https://6ix.com/company/syngene-international-limited/news/press-release-nov-05-2025-9</link>
<guid isPermaLink="true">https://6ix.com/company/syngene-international-limited/news/press-release-nov-05-2025-9</guid>
<pubDate>Thu, 06 Nov 2025 01:49:42 GMT</pubDate>
<description>Syngene International Limited has informed the Exchange regarding a press release dated November 05, 2025, titled "Second quarter revenue from operations grows 4% sequentially and 2% year-on-year to Rs. 911 Cr 1st half revenue from operations up 6%".</description>
</item>
<item>
<title>Syngene International announces plans to add bioconjugation suite for end-to-end Antibody-Drug Conjugates Development</title>
<link>https://6ix.com/company/syngene-international-limited/news/syngene-international-announces-plans-to-add-bioconjugation-suite-for-end-to-end-antibody-drug-conjugates-development</link>
<guid isPermaLink="true">https://6ix.com/company/syngene-international-limited/news/syngene-international-announces-plans-to-add-bioconjugation-suite-for-end-to-end-antibody-drug-conjugates-development</guid>
<pubDate>Mon, 27 Oct 2025 18:27:00 GMT</pubDate>
<description>Syngene International, a global contract research, development and manufacturing organization (CRDMO), is adding a GMP bioconjugation suite at its commercial biologics facility [Unit 3] in Bengaluru. With this new capability, Syngene will offer fully integrated, end-to-end services for antibody-drug conjugates (ADCs) – from discovery through to GMP manufacturing – placing it among a handful of CDMOs with full-service capabilities.</description>
</item>
<item>
<title>Orocidin develops novel cGMP manufacturing process in collaboration with Syngene</title>
<link>https://6ix.com/company/syngene-international-limited/news/orocidin-develops-novel-cgmp-manufacturing-process-in-collaboration-with-syngene</link>
<guid isPermaLink="true">https://6ix.com/company/syngene-international-limited/news/orocidin-develops-novel-cgmp-manufacturing-process-in-collaboration-with-syngene</guid>
<pubDate>Mon, 20 Oct 2025 13:00:00 GMT</pubDate>
<description>The partnership addressed complex peptide synthesis and purification challenges to achieve high yield and purity suitable for clinical use BEVERLY HILLS, California, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, announced the development of a unique</description>
</item>
<item>
<title>Syngene International invests in dedicated peptide laboratory and advanced automation</title>
<link>https://6ix.com/company/syngene-international-limited/news/syngene-international-invests-in-dedicated-peptide-laboratory-and-advanced-automation</link>
<guid isPermaLink="true">https://6ix.com/company/syngene-international-limited/news/syngene-international-invests-in-dedicated-peptide-laboratory-and-advanced-automation</guid>
<pubDate>Fri, 17 Oct 2025 14:16:00 GMT</pubDate>
<description>Syngene International, a global contract research, development, and manufacturing organization (CRDMO), announced site upgrades to accelerate drug discovery and development, helping clients bring novel therapies to market faster. The investments included a dedicated, state-of-the-art peptide laboratory in Bengaluru and the integration of advanced automation across DMPK (Drug Metabolism and Pharmacokinetics) and Direct-to-Biology (D2B) workflows in Hyderabad— boosting scalability, cost-efficiency</description>
</item>
<item>
<title>Press Release Jul 23 2025</title>
<link>https://6ix.com/company/syngene-international-limited/news/press-release-jul-23-2025-3</link>
<guid isPermaLink="true">https://6ix.com/company/syngene-international-limited/news/press-release-jul-23-2025-3</guid>
<pubDate>Wed, 23 Jul 2025 19:17:53 GMT</pubDate>
<description>Syngene International Limited has informed the Exchange regarding a press release dated July 23, 2025, titled "First quarter revenue from operations up 11% year-on-year to Rs. 875 Cr".</description>
</item>
<item>
<title>Syngene International announces third year of STEM scholarship and mentorship program for women in collaboration with RICH</title>
<link>https://6ix.com/company/syngene-international-limited/news/syngene-international-announces-third-year-of-stem-scholarship-and-mentorship-program-for-women-in-collaboration-with-rich</link>
<guid isPermaLink="true">https://6ix.com/company/syngene-international-limited/news/syngene-international-announces-third-year-of-stem-scholarship-and-mentorship-program-for-women-in-collaboration-with-rich</guid>
<pubDate>Thu, 10 Jul 2025 09:11:00 GMT</pubDate>
<description>Syngene International Ltd., an integrated research, development, and manufacturing services organization, in partnership with the Research and Innovation Circle of Hyderabad (RICH) and Biocon Foundation, announced the launch of the third cohort of its flagship scholarship, mentoring and industry orientation program for women in STEM (science, technology, engineering and mathematics). Designed to empower women from tier two and three institutions, the program offers structured mentorship, financi</description>
</item>
<item>
<title>Press Release Apr 23 2025</title>
<link>https://6ix.com/company/syngene-international-limited/news/press-release-apr-23-2025-5</link>
<guid isPermaLink="true">https://6ix.com/company/syngene-international-limited/news/press-release-apr-23-2025-5</guid>
<pubDate>Thu, 24 Apr 2025 00:00:46 GMT</pubDate>
<description>Syngene International Limited has informed the Exchange regarding a press release dated April 23, 2025, titled "Syngene Results Q4 FY25 and full-year FY25 - Fourth quarter revenue from operations up 11% year-on-year to Rs. 1,018 Cr Full-year revenue from operations up 4% to Rs. 3,642 Cr".</description>
</item>
<item>
<title>Press Release Mar 19 2025</title>
<link>https://6ix.com/company/syngene-international-limited/news/press-release-mar-19-2025-2</link>
<guid isPermaLink="true">https://6ix.com/company/syngene-international-limited/news/press-release-mar-19-2025-2</guid>
<pubDate>Thu, 20 Mar 2025 03:36:13 GMT</pubDate>
<description>Syngene International Limited has informed the Exchange regarding a press release dated March 19, 2025, titled "Syngene concludes the acquisition of Biologics Manufacturing Facility from Emergent BioSolutions Inc.".</description>
</item>
<item>
<title>Press Release Mar 10 2025</title>
<link>https://6ix.com/company/syngene-international-limited/news/press-release-mar-10-2025-5</link>
<guid isPermaLink="true">https://6ix.com/company/syngene-international-limited/news/press-release-mar-10-2025-5</guid>
<pubDate>Mon, 10 Mar 2025 22:46:39 GMT</pubDate>
<description>Syngene International Limited has informed the Exchange regarding a press release dated March 10, 2025, titled "Syngene Acquires its First Manufacturing Facility in the US".</description>
</item>
<item>
<title>Press Release Feb 10 2025</title>
<link>https://6ix.com/company/syngene-international-limited/news/press-release-feb-10-2025-8</link>
<guid isPermaLink="true">https://6ix.com/company/syngene-international-limited/news/press-release-feb-10-2025-8</guid>
<pubDate>Tue, 11 Feb 2025 00:52:13 GMT</pubDate>
<description>Syngene International Limited has informed the Exchange regarding a press release dated February 10, 2025, titled "Syngene International announces Leadership changes".</description>
</item>
<item>
<title>Press Release Jan 23 2025</title>
<link>https://6ix.com/company/syngene-international-limited/news/press-release-jan-23-2025-7</link>
<guid isPermaLink="true">https://6ix.com/company/syngene-international-limited/news/press-release-jan-23-2025-7</guid>
<pubDate>Thu, 23 Jan 2025 20:35:36 GMT</pubDate>
<description>Syngene International Limited has informed the Exchange regarding a press release dated January 23, 2025, titled "Syngene reports third quarter results.".</description>
</item>
<item>
<title>Press Release Oct 23 2024</title>
<link>https://6ix.com/company/syngene-international-limited/news/press-release-oct-23-2024-13</link>
<guid isPermaLink="true">https://6ix.com/company/syngene-international-limited/news/press-release-oct-23-2024-13</guid>
<pubDate>Wed, 23 Oct 2024 19:33:23 GMT</pubDate>
<description>Syngene International Limited has informed the Exchange regarding a press release dated October 23, 2024, titled "Syngene reports second quarter results".</description>
</item>
<item>
<title>Press Release Jul 24 2024</title>
<link>https://6ix.com/company/syngene-international-limited/news/press-release-jul-24-2024-4</link>
<guid isPermaLink="true">https://6ix.com/company/syngene-international-limited/news/press-release-jul-24-2024-4</guid>
<pubDate>Wed, 24 Jul 2024 19:16:45 GMT</pubDate>
<description>Syngene International Limited has informed the Exchange regarding a press release dated July 24, 2024, titled "Syngene reports first quarter results".</description>
</item>
<item>
<title>Press Release Apr 24 2024</title>
<link>https://6ix.com/company/syngene-international-limited/news/press-release-apr-24-2024-9</link>
<guid isPermaLink="true">https://6ix.com/company/syngene-international-limited/news/press-release-apr-24-2024-9</guid>
<pubDate>Wed, 24 Apr 2024 23:58:12 GMT</pubDate>
<description>Syngene International Limited has informed the Exchange regarding a press release dated April 24, 2024, titled "Syngene reports full year and fourth quarter results".</description>
</item>
<item>
<title>Press Release Jan 25 2024</title>
<link>https://6ix.com/company/syngene-international-limited/news/press-release-jan-25-2024-7</link>
<guid isPermaLink="true">https://6ix.com/company/syngene-international-limited/news/press-release-jan-25-2024-7</guid>
<pubDate>Thu, 25 Jan 2024 19:41:46 GMT</pubDate>
<description>Syngene International Limited has informed the Exchange regarding a press release dated January 25, 2024, titled "Syngene reports third quarter results: revenue from operations up 9% to Rs. 854 crores, PAT up 4% to Rs. 115 crores".</description>
</item>
<item>
<title>Press Release Dec 01 2023</title>
<link>https://6ix.com/company/syngene-international-limited/news/press-release-dec-01-2023-6</link>
<guid isPermaLink="true">https://6ix.com/company/syngene-international-limited/news/press-release-dec-01-2023-6</guid>
<pubDate>Sat, 02 Dec 2023 00:59:19 GMT</pubDate>
<description>Syngene International Limited has informed the Exchange regarding a press release dated December 01, 2023, titled "Syngene concludes the acquisition of biologics manufacturing facility from Stelis Biopharma Ltd".</description>
</item>
</channel>
</rss>